News
In a phase 2 trial of peanut oral immunotherapy (OIT) involving 21 adults, 67% achieved maintenance dose tolerance, with the median tolerated dose increasing 100-fold from 30 mg to 3000 mg.
Of 76 patients aged less than 4 years participating in peanut OIT, 19 were considered low-risk candidates for an accelerated initial dose escalation based on a history of allergic reaction to ...
Oregon Tech healthcare students Students in Oregon Tech's health-related programs. Klamath Falls, Ore., April 21, 2025 (GLOBE ...
The proposed future medical school is part of Oregon Tech’s broader health and wellness initiative, in collaboration with community partners and state agencies. This initiative aims to create ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results